A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205   with or without intravesical Bacillus Calmette-Guerin (BCG) in   BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC):   CheckMate 9UT.

Title:: A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
Document type:: Meeting Abstract
Author(s):: Hahn, Noah M.; Chang, Sam S.; Meng, Maxwell; Shore, Neal D.; Konety, Badrinath R.; Steinberg, Gary D.; Gschwend, Juergen E.; Nishiyama, Hiroyuki; Redorta, Juan Palou; Taylor, John Arthur; Elegbe, Ayanbola; Lambert, Alexandre; Zhu, Li; Ishii, Yuko; Maeda, Toshiki; Raybold, Bradley; Grossfeld, Gary; Fischer, Bruce S.; Rutstein, Mark; Witjes, Alfred
Journal title abbreviation:: J Clin Oncol
Year:: 2019
Journal volume:: 37 Suppl S
Journal issue:: 7
Fulltext / DOI:: doi:10.1200/JCO.2019.37.7_suppl.TPS493
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: